341 related articles for article (PubMed ID: 30684016)
1. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
[TBL] [Abstract][Full Text] [Related]
2. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice.
Teraoka Y; Uchida T; Imamura M; Osawa M; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K;
Biochem Biophys Res Commun; 2018 Jun; 500(2):152-157. PubMed ID: 29621544
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed.
Yoshida K; Hai H; Tamori A; Teranishi Y; Kozuka R; Motoyama H; Kawamura E; Hagihara A; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28467359
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.
Nguyen D; Smith D; Vaughan-Jackson A; Magri A; ; Barnes E; Simmonds P
J Hepatol; 2020 Oct; 73(4):794-799. PubMed ID: 32470499
[TBL] [Abstract][Full Text] [Related]
6. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K
J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus NS5A inhibitors and drug resistance mutations.
Nakamoto S; Kanda T; Wu S; Shirasawa H; Yokosuka O
World J Gastroenterol; 2014 Mar; 20(11):2902-12. PubMed ID: 24659881
[TBL] [Abstract][Full Text] [Related]
9. Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection.
Takaki S; Imamura M; Yamaguchi S; Fukuhara T; Mori N; Tsuji K; Ohya K; Hayes CN; Aikata H; Chayama K
Clin J Gastroenterol; 2020 Dec; 13(6):1233-1238. PubMed ID: 32656649
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hepatitis C virus genotype 3-infection.
Pol S; Vallet-Pichard A; Corouge M
Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
[TBL] [Abstract][Full Text] [Related]
11. Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients.
Nitta S; Asahina Y; Kato T; Tsuchiya J; Inoue-Shinomiya E; Sato A; Tsunoda T; Miyoshi M; Kawai-Kitahata F; Murakawa M; Itsui Y; Nakagawa M; Azuma S; Kakinuma S; Hikita H; Takehara T; Watanabe M
Sci Rep; 2019 Apr; 9(1):5722. PubMed ID: 30952914
[TBL] [Abstract][Full Text] [Related]
12. NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir.
Uemura H; Uchida Y; Kouyama JI; Naiki K; Tsuji S; Sugawara K; Nakao M; Motoya D; Nakayama N; Imai Y; Tomiya T; Mochida S
J Gastroenterol; 2019 May; 54(5):459-470. PubMed ID: 30612205
[TBL] [Abstract][Full Text] [Related]
13. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
[TBL] [Abstract][Full Text] [Related]
14. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
Sarrazin C; Dvory-Sobol H; Svarovskaia ES; Doehle BP; Pang PS; Chuang SM; Ma J; Ding X; Afdhal NH; Kowdley KV; Gane EJ; Lawitz E; Brainard DM; McHutchison JG; Miller MD; Mo H
Gastroenterology; 2016 Sep; 151(3):501-512.e1. PubMed ID: 27296509
[TBL] [Abstract][Full Text] [Related]
16. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice.
Ohya K; Imamura M; Teraoka Y; Uchida T; Fujino H; Nakahara T; Ono A; Murakami E; Yamauchi M; Kawaoka T; Miki D; Tsuge M; Abe-Chayama H; Hayes CN; Aikata H; Ishida Y; Tateno C; Song H; Miyayama Y; Hijikata M; Chayama K
Biochem Biophys Res Commun; 2021 Jun; 559():78-83. PubMed ID: 33932902
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
Rossetti B; Paglicci L; Di Maio VC; Cassol C; Barbaliscia S; Paolucci S; Bruzzone B; Coppola N; Montagnani F; Micheli V; Monno L; Zanelli G; Santantonio T; Cuomo N; Caudai C; Zazzi M; Ceccherini-Silberstein F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet C
Infez Med; 2021 Jun; 29(2):242-251. PubMed ID: 34061790
[TBL] [Abstract][Full Text] [Related]
18. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
Jacobson I; Zeuzem S; Flisiak R; Knysz B; Lueth S; Zarebska-Michaluk D; Janczewska E; Ferenci P; Diago M; Zignego AL; Safadi R; Baruch Y; Abdurakhmanov D; Shafran S; Thabut D; Bruck R; Gadano A; Thompson AJ; Kopit J; McPhee F; Michener T; Hughes EA; Yin PD; Noviello S
World J Gastroenterol; 2016 Mar; 22(12):3418-31. PubMed ID: 27022224
[TBL] [Abstract][Full Text] [Related]
19. Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
Kai Y; Hikita H; Tatsumi T; Nakabori T; Saito Y; Morishita N; Tanaka S; Nawa T; Oze T; Sakamori R; Yakushijin T; Hiramatsu N; Suemizu H; Takehara T
J Gastroenterol; 2015 Nov; 50(11):1145-51. PubMed ID: 26208695
[TBL] [Abstract][Full Text] [Related]
20. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
Friborg J; Levine S; Chen C; Sheaffer AK; Chaniewski S; Voss S; Lemm JA; McPhee F
Antimicrob Agents Chemother; 2013 Mar; 57(3):1312-22. PubMed ID: 23274666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]